{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:41:22Z","timestamp":1788352882631,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.abd.2024.05.005","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T12:28:13Z","timestamp":1736425693000},"page":"293-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7956-4033","authenticated-orcid":false,"given":"Leyla Baykal","family":"Sel\u00e7uk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1431-2203","authenticated-orcid":false,"given":"Hande Ermi\u015f","family":"Akku\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3052-5014","authenticated-orcid":false,"given":"Burak","family":"Ak\u015fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-4325","authenticated-orcid":false,"given":"Deniz Aksu","family":"Ar\u0131ca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2024.05.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15214","article-title":"Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study","volume":"35","author":"Ruggiero","year":"2022","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2024.05.005_bib0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 Inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.abd.2024.05.005_bib0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2024.05.005_bib0020","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2024.05.005_bib0025","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2024.05.005_bib0030","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2024.05.005_bib0035","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2024.05.005_bib0040","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2024.05.005_bib0045","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jaad.2021.01.025","article-title":"Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison","volume":"85","author":"Ruggiero","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2024.05.005_bib0050","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/ijd.16849","article-title":"Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas","volume":"62","author":"Vaiopoulos","year":"2023","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.abd.2024.05.005_bib0055","doi-asserted-by":"crossref","first-page":"e644","DOI":"10.1111\/jdv.16511","article-title":"Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study","volume":"34","author":"Fougerousse","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2024.05.005_bib0060","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1111\/jdv.16715","article-title":"Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study","volume":"34","author":"Benhadou","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2024.05.005_bib0065","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.3390\/jcm9072170","article-title":"Use of Guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study","volume":"9","author":"Galluzzo","year":"2020","journal-title":"J Clin Med."},{"key":"10.1016\/j.abd.2024.05.005_bib0070","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1111\/jdv.17003","article-title":"A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic","volume":"35","author":"Hansel","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2024.05.005_bib0075","article-title":"Risankizumab shows high efficacy and maintenance in improvement of response until week 52","volume":"35","author":"Mastorino","year":"2022","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2024.05.005_bib0080","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s13555-021-00556-2","article-title":"Risankizumab for the treatment of moderate-to-severe psoriasis: real-life multicenter experience from the Czech Republic","volume":"11","author":"Gkalpakiotis","year":"2021","journal-title":"Dermatol Ther (Heidelb)."},{"key":"10.1016\/j.abd.2024.05.005_bib0085","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s13555-022-00795-x","article-title":"Real-life effectiveness and safety of risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study","volume":"12","author":"Gargiulo","year":"2022","journal-title":"Dermatol Ther (Heidelb)."},{"key":"10.1016\/j.abd.2024.05.005_bib0090","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1111\/jdv.17656","article-title":"A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis","volume":"36","author":"Hansel","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2024.05.005_bib0095","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/bjd.19575","article-title":"Efficacy of in-class interleukin-23 inhibitor switching: risankizumab following guselkumab failure in moderate-to-severe psoriasis treatment","volume":"184","author":"Reddy","year":"2021","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2024.05.005_bib0100","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2022.2133531","article-title":"Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis","volume":"34","author":"Elgaard","year":"2023","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.abd.2024.05.005_bib0105","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/jdv.18218","article-title":"Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab","volume":"36","author":"Gerdes","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2024.05.005_bib0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1169735","article-title":"Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system","volume":"14","author":"Shu","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.abd.2024.05.005_bib0115","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv Ther."},{"key":"10.1016\/j.abd.2024.05.005_bib0120","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2023.03.035","article-title":"Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: pooled results from the VOYAGE 1 and VOYAGE 2 trials","volume":"89","author":"Blauvelt","year":"2023","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2024.05.005_bib0125","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1080\/14712598.2022.2090835","article-title":"Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year","volume":"22","author":"Galluzzo","year":"2022","journal-title":"Expert Opin Biol Ther."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059624002526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059624002526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:52Z","timestamp":1747666852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059624002526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0365059624002526"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2024.05.005","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}